Panic Disorder Comorbidity With Heart Disease in SMI Populations

Panic disorder and heart disease form a dangerous convergence for people living with serious mental illness (SMI). Panic disorder is more prevalent in this population and independently associated with a 47% higher risk of coronary heart disease, yet overlapping symptoms and fragmented services can obscure both conditions. Good care must bring cardiac assessment, psychiatric treatment, and practical support together.

Why SMI patients carry a cardiovascular burden that goes beyond their psychiatric diagnosis

People with SMI face substantially higher rates of cardiovascular mortality and sudden cardiac death than the general population. This pattern extends across sexes, ages, and ethnic groups, making it difficult to dismiss as a problem confined to a narrow subgroup. The disparity reflects compounding forces, including distress, lifestyle risk factors, comorbid conditions, and the effects of some psychiatric medications. At the population level, these forces create a cardiovascular burden that cannot be understood through psychiatric diagnosis alone.

The 2025 ESC Clinical Consensus Statement identifies this burden as an urgent clinical problem and calls for cardiovascular risk scoring recalibrated for people with SMI. That recommendation raises a basic question about the reach of cardiac care. Who has benefited from its recent advances? The cardiovascular mortality gap has not narrowed for people with SMI as it has for the general population, suggesting that improvements in treatment have largely bypassed this group. Panic disorder therefore enters a population already facing elevated risk and unequal access to the gains of modern cardiovascular care.

How panic disorder independently raises coronary heart disease risk

A meta-analysis drawing on tens of thousands of cardiac events found an adjusted hazard ratio of 1.47 for developing coronary heart disease among people with panic disorder. This represents a 47% higher hazard after full statistical adjustment, rather than simply an excess explained by the lifestyle and behavioral factors accounted for in the analysis. Panic disorder can cause frightening sensations that feel like heart disease. It is also a documented marker of increased risk of developing coronary disease.

What does that finding establish when panic disorder and SMI coexist? It supports concern about a convergence of risks, but it does not provide a combined estimate for this specific population. The distinction is important for interpreting the evidence. Statistical adjustment strengthens the case for an independent association without, by itself, proving the biological route through which panic affects the heart.

The biological mechanism connecting panic disorder and vascular disease

Serotonin provides one such connection between psychiatric and vascular function. Also known as 5-hydroxytryptamine, or 5-HT, it is implicated in the etiology of panic disorder and directly influences vascular tone, the degree of tension in blood vessel walls. Its actions through 5-HT1B and 5-HT2A receptors affect nitric oxide production and the vasomotor response. A signaling system involved in panic can also influence how blood vessels function.

The same system affects platelet activation and aggregation, which may be another way it harms blood vessels. Repeated dysregulation during panic episodes may contribute cumulatively to dysfunction of the endothelium, the lining of blood vessels. The PI3K/Akt/eNOS signaling pathway is also implicated in serotonin’s influence on endothelial function, among interacting pathways whose roles remain unsettled. Sympathetic nervous system activity and chronic inflammation are other ways that psychiatric disorders, including anxiety, are linked to metabolic syndrome and residual cardiovascular risk.

This biology raises an important treatment question. If serotonin influences both panic and vascular function, could treating one improve the other? SSRIs have shown promise in improving endothelial function, but studies disagree on their effects on cardiovascular outcomes. A change in vascular function alone does not prove that there will be fewer cardiac events.

Why the symptom overlap between panic and cardiac disease creates a dangerous diagnostic trap

The Wyckoff Heights case shows how difficult this distinction can become in practice. A 45-year-old woman diagnosed with panic disorder had no success with any anti-anxiolytic trials and made several ER visits at another facility, where her cardiac workups were negative. She was ultimately found to have supraventricular tachycardia, specifically atrioventricular nodal reentrant tachycardia. The eventual diagnosis changed the interpretation of her symptoms. What had been treated as panic was an arrhythmia, illustrating how repeated encounters can occur without resolving the central diagnostic question.

Panic attacks can produce palpitations, chest pain, dyspnea, dizziness, and a fear of dying. Without careful workup, those symptoms can be clinically indistinguishable from arrhythmia, acute coronary syndrome, and other cardiac emergencies. The diagnostic risk runs in both directions. Cardiac disease may be assigned a psychiatric explanation, while panic disorder may remain unrecognized when attention stays on a suspected cardiac cause. Neither error is harmless, because each can leave the actual condition untreated.

Treatment delays for panic disorder can span nine to fifteen years, creating a long interval in which its cardiovascular effects may accumulate. That range should not be read as an SMI-specific estimate or attributed entirely to diagnostic confusion. For people with SMI, however, stigma, communication barriers, and assumptions about physical complaints add further obstacles to recognition. A psychiatric diagnosis can skew how later symptoms are understood. Clinicians must determine which conditions are present when both “mental” and “physical” explanations remain plausible.

How structural factors — poverty, smoking, food insecurity, and medication access — amplify the compounded risk

A correct diagnosis does not remove the conditions that make treatment difficult to sustain. Smoking is a central contributor to the cardiovascular mortality gap, with a majority of people with SMI smoking compared with a small fraction of the general adult population. Food insecurity can also cause harm by pushing people toward diets high in fat and sodium. Poverty also constrains access to prescribed treatment. Families facing financial scarcity may have to choose food over medication, making an apparently clinical failure inseparable from the household’s resources.

Understanding medication non-adherence in that situation as a consequence of deprivation changes how the problem is understood. A prescription alone cannot help someone get medication they have no way to obtain, just as knowing the risks of a diet cannot remove food insecurity. Describing these outcomes only as behavioral choices obscures the constraints that produce them. It also directs attention away from the practical support needed to make treatment possible.

Poor housing, social isolation, and limited transportation also make it harder to get psychiatric and cardiac follow-up. These barriers can persist after both conditions have been identified correctly, undermining continuity of care. The effects reach across the care pathway. Structural conditions contribute both to the onset of cardiovascular disease and to failures in its ongoing management.

How the healthcare system compounds the problem through fragmented care and disparate cardiac treatment

People with SMI have been found 47% less likely to undergo invasive coronary procedures than the general population. They are also significantly less likely to receive standard secondary prevention medications after cardiovascular disease is identified. These disparities indicate a system-level problem extending beyond whether an individual clinician correctly interprets chest pain. The pathway from diagnosis to cardiac treatment is itself unequal.

Psychiatric and cardiac services are typically organized as separate systems with limited communication between them. Someone getting psychiatric care for panic disorder may never have their cardiovascular risk checked, while someone getting cardiac care for chest pain may never be screened for panic disorder or SMI. Each service can see only part of the problem. Standard cardiovascular risk tools add another limitation because they were not designed for this population and systematically underestimate its risk. The consensus statement’s call for recalibration would change the basis on which clinicians make decisions, going beyond an extra assessment.

The Genomic Psychiatry Cohort study used semi-structured interviews with African American adults living with SMI and cardiovascular disease to learn about barriers from their lived experience. The 2025 study identified interacting illnesses, self-management challenges, structural deprivation, and healthcare distrust as compounding obstacles. It was among the first studies of its kind focused on this intersection in that population. That limited representation raises a further question. How well can care pathways address affected communities when the research informing their design has so rarely centered those communities’ experiences?

What integrated, peer-supported care looks like in practice — and what the evidence shows

Peer support offers a way to strengthen the engagement and self-management that fragmented care often fails to sustain. Interventions in cardiovascular disease have demonstrated improvements in disease self-management and self-efficacy in the short term and across the first year after coronary heart disease diagnosis. These are meaningful but bounded findings. More confidence and a greater ability to manage illness do not prove that every health outcome has improved. That limit matters especially when using cardiovascular evidence to guide care for people who also have to cope with SMI.

A 2025 meta-analysis found no statistically significant improvement in health-related quality of life, depression, or anxiety six months after people were diagnosed with coronary heart disease. That finding tempers claims about what peer support achieves in the short term without erasing evidence of improved self-management. The outcome being measured changes the conclusion. Support may strengthen the conditions for effective care even when broader improvements are not detectable at that time point. Evidence of engagement should not be presented as proof of reduced cardiac mortality.

The PRIMROSE and PRIMROSE-A interventions in the UK brought behavioral change support into appointments for people with SMI. Their work included personalized care planning, goal setting, treatment adherence monitoring, and connections to supportive services. PRIMROSE-A incorporated a peer coach with lived experience of SMI. The TTIM intervention used peer educators with lived experience of SMI and diabetes working with nurse educators to teach and model self-management. Though that intervention was for diabetes rather than cardiac disease, it offers a model of how to help people manage psychiatric and physical illness together.

People whose healthcare encounters have involved dismissal, misdiagnosis, or undertreatment may need support that helps bridge distrust as well as explain a care plan. Community-based support can address housing, food, medication access, and behavioral health together, meeting people where they are. This is practical integration rather than referral alone. It links clinical treatment to the support people need to get medication, attend appointments, and keep up care outside the consulting room.

What holistic care for this population must actually include

Adequate care requires simultaneous attention to biological risk, psychiatric symptoms, and structural barriers rather than sequential treatment across disconnected services. Clinically, that means proactive screening, active risk-factor mitigation, and cardiovascular risk tools recalibrated for people with SMI. Differential diagnosis must also become a shared competency across psychiatric and cardiac settings. What seems to be panic may be arrhythmia, and chest pain may involve panic disorder, so safe care in each specialty depends on taking the other’s work into account.

That shared responsibility must extend beyond assessment to the feasibility of treatment. Stabilizing housing, securing food access, and supporting medication adherence are clinical interventions in this context because they address conditions that drive cardiovascular risk and disrupt care. Peer-supported, community-anchored services can help connect those needs with psychiatric and cardiac management. Such support helps make specialist treatment usable for people whose health depends on more than what happens during an appointment.

Recovery is possible, and the evidence base for integrated care is growing even as questions about specific outcomes remain. Health plans, provider systems, and peer support organizations have complementary roles in building pathways that can deliver this care at scale. The necessary components are already identifiable. People with SMI do not experience cardiac health, psychiatric stability, nutrition, housing, and social connection as independent problems, and services cannot adequately treat them that way. The central gap is not a lack of knowledge that care must be integrated, but the will and system design to make that knowledge operative.